Fig. 2: IGF2BP3 expression in NSCLC.

a Expression distribution of m6A modulator genes in normal and NSCLC tissues based on TCGA database analysis (n = 1017 NSCLC tumor tissues and n = 686 normal tissues). b Molecular characterization of m6A regulators in NSCLC with and without metastasis using TCGA data (n = 520 without metastasis and n = 485 with metastasis). In box plots, the center line represents the median, the bounds of the box indicate the interquartile range from the 25th to 75th percentile, and whiskers extend to the 1.5× interquartile range. Outliers beyond this range are plotted individually. c The IGF2BP3 gene expression profiles in human NSCLC within the GEPIA database (n = 483 lung adenocarcinoma tumor tissues and n = 59 normal tissues, n = 486 lung squamous cell carcinoma tumor tissues and n = 50 normal tissues). d The correlation between IGF2BP3 expression and survival rate of NSCLC patients within the GEPIA database (n = 481 patients). e Immunohistochemical staining of IGF2BP3 in human NSCLC tissues and adjacent tissues and f quantitative analysis of relative IGF2BP3-positive expression (n = 4 patients), scale bar, 50 μm. g Immunohistochemical staining of IGF2BP3 in NSCLC tissues from mice, scale bars, 20 μm. h qRT-PCR analysis of IGF2BP3 mRNA levels in NSCLC and normal tissues from mice (n = 3 mice). i qRT-PCR analysis of IGF2BP3 mRNA levels and j, k western blot analysis of IGF2BP3 protein levels in LLC cells treated with OST and IGF2BP3 siRNA (n = 4 independent experiments). Data are shown as mean ± SD. a and b were analyzed by two-sided Wilcox test. d was assessed using the log-rank (Mantel-Cox) test. h, i and k were calculated using the one-way ANOVA with a Tukey post hoc test. c and f were analyzed by a two-sided t-test. Source data are provided as a Source Data file.